 |
|
Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002
The Importance of Reporting Suspected Reactions
Diane K. Wysowski, PhD;
Lynette Swartz, MEd, MBA
Arch Intern Med. 2005;165:1363-1369.
Background The Adverse Event Reporting System is the primary surveillance database used by the Food and Drug Administration for identifying postmarketing drug safety problems.
Methods We analyzed all reports of suspected adverse drug reactions submitted to the Food and Drug Administration from the inception of the Adverse Event Reporting System database in 1969 through December 2002. We documented drug withdrawals and restricted distribution programs based on safety concerns.
Results During the 33-year period from 1969 when adverse drug event reporting was initiated through 2002, about 2.3 million case reports of adverse events for the cumulative number of approximately 6000 marketed drugs were entered in the database. Most reports were for female patients. During this period, numerous drug reactions have been identified and added to the product labeling as boxed warnings, warnings, precautions, contraindications, and adverse reactions. More than 75 drugs/drug products have been removed from the market due to safety problems. In addition, 11 drugs have special requirements for prescriptions or have restricted distribution programs. Drugs withdrawn or restricted represent a small proportion (about 1%) of marketed drugs.
Conclusions The Food and Drug Administration’s Adverse Event Reporting System is the primary surveillance database used for the identification of safety problems of marketed drugs. Despite the limitations of underreporting, differential reporting, and uneven quality, submitted reports often allow the identification of serious adverse events that are added to the product labeling information. In rare instances, additional regulations, up to and including market removal, have been required. We encourage physicians, pharmacists, other health care professionals, and patients to continue to report serious suspected and known adverse drug reactions to manufacturers and the Food and Drug Administration.
Author Affiliations: Office of Drug Safety, Food and Drug Administration, Rockville, Md.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective
Tremlett and Oger
Mult Scler 2008;14:94-105.
ABSTRACT
Using population-based routine data for evidence-based health policy decisions: lessons from three examples of setting and evaluating national health policy in Australia, the UK and the USA
Morrato et al.
J Public Health (Oxf) 2007;29:463-471.
ABSTRACT
| FULL TEXT
Bleeding Complications With Warfarin Use: A Prevalent Adverse Effect Resulting in Regulatory Action
Wysowski et al.
Arch Intern Med 2007;167:1414-1419.
ABSTRACT
| FULL TEXT
POSTMARKETING MODIFICATIONS IN THE SAFETY LABELING OF THE NEW ANTIEPILEPTICS
Buck et al.
Neurology 2007;68:1536-1537.
FULL TEXT
The FDA and drug safety: a proposal for sweeping changes.
Furberg et al.
Arch Intern Med 2006;166:1938-1942.
ABSTRACT
| FULL TEXT
An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial.
Figueiras et al.
JAMA 2006;296:1086-1093.
ABSTRACT
| FULL TEXT
Effect of internal reporting criteria on suspected adverse drug reactions submitted to MedWatch
Smith et al.
Am J Health Syst Pharm 2006;63:949-952.
FULL TEXT
Clinical Trials in the Wake of Vioxx: Requiring Statistically Extreme Evidence of Benefit to Ensure the Safety of New Drugs
Roth-Cline
Circulation 2006;113:2253-2259.
FULL TEXT
Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks.
Qureshi and Fischer
Arch Dermatol 2006;142:633-637.
FULL TEXT
Allergic Reactions After the Implantation of Drug-Eluting Stents: Is it the Pill or the Polymer?
Azarbal and Currier
J Am Coll Cardiol 2006;47:182-183.
FULL TEXT
|
